Brazil · Delayed Price · Currency is BRL Blau Farmacêutica Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw strategic divestment, record investments in biotech, and improved margins despite a 3% revenue drop. Net income rose 39%, and new launches plus expanded capacity set the stage for stronger, less volatile growth in 2026.
-
Revenue and gross margin remained strong, with net income up 52% year-over-year. Capacity constraints limited growth, but major expansions and new product launches are set to drive a 70% increase in production and 60% growth in launches over the next three years.
-
Revenue remained stable year-over-year amid capacity constraints, but gross margin and EBITDA reached post-pandemic highs. New production lines, a strong pipeline, and the Prothya exit position the company for accelerated growth and strategic investments.
-
Revenue grew 4% year-over-year in Q1 2025, with strong 15% growth in the private hospital segment and a 50% increase in net income. Investments in biotechnology and new product launches support a robust outlook, despite temporary impacts from regulatory and supply chain transitions.
Fiscal Year 2024
-
Achieved record quarterly revenue of BRL 474 million, up 31% year-over-year, with strong growth in the hospital segment and improved margins. R&D investment remained high, and integration of Bergamo advanced, while focus shifted to private market sales and Latin American expansion.
-
Q2 2024 saw record revenue and margin expansion, driven by strong private market growth, new product launches, and operational efficiencies. Strategic investments in R&D, capacity, and partnerships position the company for continued growth, with robust cash and low leverage.